Back to Results
First PageMeta Content
Health / Applied genetics / Biotechnology / AIDS / Acronyms / Syndromes / Gene therapy / RNA interference / HIV / Biology / Genetics / HIV/AIDS


Document Date: 2012-05-14 03:23:03

Open Document

File Size: 376,41 KB

Share Result on Facebook

City

Sydney / /

Company

Calimmune / Australian Securities Exchange / Benitec Biopharma Chief Investigators Group / Benitec Biopharma Ltd / /

Country

United States / Australia / /

/

Event

Business Partnership / Company Listing Change / Person Communication and Meetings / /

Facility

UCLA AIDS Institute / /

IndustryTerm

transformational technology / biopharmaceutical / HIV therapeutics / pharmaceutical industry / early technology / treatment of HIV / therapies for HIV / ddRNAi technology / platform technology / ddRNAi-based therapeutics / pharmaceutical products / stem cell technology / ddRNAi-based technology / /

MedicalCondition

serious chronic diseases / chronic cancer / cancer / HIV / disease / HIV/AIDS infection / diseases / AIDS / infectious diseases / HIV/AIDS / chronic and life-threatening conditions / /

MedicalTreatment

gene therapy / /

Organization

UCLA AIDS Institute / /

Person

Irvin Chen / Geoff Symonds / Peter French / Louis Breton / David Baltimore / John Rossi / David Baltimore (Caltech) / /

/

Position

Chief Scientific Officer / Professor / Chief Executive Officer / /

ProvinceOrState

California / /

Technology

gene therapy / early technology / ddRNAi-based technology / platform technology / transformational technology / ddRNAi technology / stem cell technology / /

URL

www.benitec.com / /

SocialTag